2005 Annual Meeting | Clinical Trials in Dementia

Date Saturday 04/09/05

Time 06:00 PM - 08:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Kick-Off Program

Director(s) David S. Knopman, MD, FAAN

Topic(s) Aging/Dementia/Degenerative Disease

Learning Objectives Upon completion:
Participants should be familiar with the methodological strengths and weaknesses of currently published clinical trials for prevention of mild cognitive impairment and Alzheimer's disease and should be familiar with current and future drugs of interest in Alzheimer's therapeutics.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Resident

Event Timeline
06:00 PM - 06:05 PM		Introduction to Clinical Trials in Dementia David S. Knopman, MD, FAAN
06:00 PM - 08:00 PM		Refreshments
06:05 PM - 06:45 PM		The Quest to Prevent Alzheimer's Disease: Experience of the Women's Health Initiative Sally Shumaker, PhD
06:45 PM - 07:20 PM		Treatment of Mild Cognitive Impairment to Delay the Appearance of Alzheimer's Disease Ronald C. Petersen, MD, PhD, FAAN
07:20 PM - 07:50 PM		Where We Stand with Symptomatic Treatments for Alzheimer's Disease David S. Knopman, MD, FAAN
07:50 PM - 08:00 PM		Discussion

Faculty Disclosures
Ronald C. Petersen, MD, PhD, FAAN	Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
David S. Knopman, MD, FAAN	Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Sally Shumaker, PhD	No disclosure on file

��ɫ��

��ɫ��